Skip to main content
. Author manuscript; available in PMC: 2010 Aug 17.
Published in final edited form as: Am J Ophthalmol. 2009 Aug 6;148(5):696–703.e1. doi: 10.1016/j.ajo.2009.06.003

FIGURE 1.

FIGURE 1

Anterior chamber (AC) cells over time in patients with juvenile idiopathic arthritis (JIA) receiving high-dose daclizumab. Grading of AC cells by weeks after intravenous daclizumab in each participant’s right (on the left) and left (on the right) eyes are demonstrated. Note that Patient 4 was considered an ocular treatment failure.